$RCEL
AVITA Medical, Inc.

2020 Q2 Form 10-K Financial Statement

#000119312520233145 Filed on August 27, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q2
Revenue $3.877M $3.877M $2.455M
YoY Change 57.92% 126.73%
Cost Of Revenue $874.0K $634.0K $505.0K
YoY Change 73.07% 117.12%
Gross Profit $3.003M $3.243M $1.950M
YoY Change 54.0% 128.7%
Gross Profit Margin 77.46% 83.65% 79.43%
Selling, General & Admin $13.97M $17.16M $7.868M
YoY Change 77.54% 146.62%
% of Gross Profit 465.17% 529.2% 403.49%
Research & Development $2.538M $2.495M $2.072M
YoY Change 22.49% 37.92%
% of Gross Profit 84.52% 76.93% 106.26%
Depreciation & Amortization $86.00K
YoY Change
% of Gross Profit 2.65%
Operating Expenses $16.51M $19.66M $10.51M
YoY Change 57.07% 110.57%
Operating Profit -$13.02M -$15.41M -$7.491M
YoY Change 73.85% 130.66%
Interest Expense $8.000K $5.000K $11.00K
YoY Change -27.27% 0.0%
% of Operating Profit
Other Income/Expense, Net $121.0K $363.0K -$246.0K
YoY Change -149.19% -27.69%
Pretax Income -$12.91M -$15.05M -$7.748M
YoY Change 66.62% 143.42%
Income Tax $4.000K $0.00 -$128.0K
% Of Pretax Income
Net Earnings -$12.91M -$15.05M -$7.620M
YoY Change 69.48% 143.42%
Net Earnings / Revenue -333.09% -388.14% -310.39%
Basic Earnings Per Share -$0.60 -$0.71 -$0.41
Diluted Earnings Per Share -$0.60 -$0.71 -$0.41
COMMON SHARES
Basic Shares Outstanding 21.37M 21.22M 18.67M
Diluted Shares Outstanding 21.37M 21.22M 18.67M

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $73.64M $79.76M $20.17M
Short-Term Investments
Other Short-Term Assets $75.00K $125.0K
YoY Change -40.0%
Inventory $1.125M $742.0K
Prepaid Expenses $792.0K $933.0K
Receivables $2.076M $1.403M
Other Receivables $356.0K $382.0K
Total Short-Term Assets $78.39M $24.13M
YoY Change 224.92%
LONG-TERM ASSETS
Property, Plant & Equipment $1.363M $1.309M
YoY Change 4.13%
Goodwill
YoY Change
Intangibles $364.0K $225.0K
YoY Change 61.78%
Long-Term Investments
YoY Change
Other Assets $1.000K $125.0K
YoY Change -99.2%
Total Long-Term Assets $4.075M $1.659M
YoY Change 145.63%
TOTAL ASSETS
Total Short-Term Assets $78.39M $24.13M
Total Long-Term Assets $4.075M $1.659M
Total Assets $82.46M $25.78M
YoY Change 219.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.709M $4.481M
YoY Change 72.04%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $0.00 $42.00K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $42.00K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.709M $4.481M
Total Long-Term Liabilities $0.00 $42.00K
Total Liabilities $10.06M $4.952M
YoY Change 103.17%
SHAREHOLDERS EQUITY
Retained Earnings -$194.9M -$152.8M
YoY Change 27.54%
Common Stock $3.000K $3.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $72.40M $81.22M $20.83M
YoY Change
Total Liabilities & Shareholders Equity $82.46M $25.78M
YoY Change 219.82%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q2
OPERATING ACTIVITIES
Net Income -$12.91M -$15.05M -$7.620M
YoY Change 69.48% 143.42%
Depreciation, Depletion And Amortization $86.00K
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73639000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20174000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2076000
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1403000
CY2020Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
356000
CY2019Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
382000
CY2020Q2 rcel Research And Development Tax Credits Current
ResearchAndDevelopmentTaxCreditsCurrent
CY2019Q2 rcel Research And Development Tax Credits Current
ResearchAndDevelopmentTaxCreditsCurrent
126000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
990000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1098000
CY2019Q2 us-gaap Restricted Cash
RestrictedCash
200000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
700000
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
201000
CY2020Q2 us-gaap Inventory Net
InventoryNet
1125000
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
429000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7709000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4481000
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
435000
CY2019Q2 us-gaap Inventory Net
InventoryNet
742000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
78387000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
24125000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1363000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1309000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2347000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
364000
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
225000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
125000
CY2020Q2 us-gaap Assets
Assets
82462000
CY2019Q2 us-gaap Assets
Assets
25784000
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4333000
CY2019Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1916000
CY2020Q2 rcel Accrued Wages And Fringe Benefits
AccruedWagesAndFringeBenefits
2816000
CY2019Q2 rcel Accrued Wages And Fringe Benefits
AccruedWagesAndFringeBenefits
2127000
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
560000
CY2019Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
438000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1917000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42000
CY2020Q2 us-gaap Liabilities
Liabilities
10061000
CY2019Q2 us-gaap Liabilities
Liabilities
4952000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
259165000
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
165473000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8146000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8184000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194913000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152828000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
72401000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
20832000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82462000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25784000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21467912
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18712996
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21467912
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18712996
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
1271000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020 us-gaap Revenues
Revenues
14263000
CY2019 us-gaap Revenues
Revenues
5474000
CY2018 us-gaap Revenues
Revenues
929000
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
2973000
CY2018 us-gaap Cost Of Revenue
CostOfRevenue
546000
CY2020 us-gaap Gross Profit
GrossProfit
11290000
CY2019 us-gaap Gross Profit
GrossProfit
4203000
CY2018 us-gaap Gross Profit
GrossProfit
383000
CY2020 us-gaap Other Operating Income
OtherOperatingIncome
3926000
CY2019 us-gaap Other Operating Income
OtherOperatingIncome
5921000
CY2018 us-gaap Other Operating Income
OtherOperatingIncome
7734000
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14813000
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12253000
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4875000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18135000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13581000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9403000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8461000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7872000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6257000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
16486000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1946000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1423000
CY2020 us-gaap Operating Expenses
OperatingExpenses
57895000
CY2019 us-gaap Operating Expenses
OperatingExpenses
35652000
CY2018 us-gaap Operating Expenses
OperatingExpenses
21958000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-42679000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-25528000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-13841000
CY2020 us-gaap Interest Expense
InterestExpense
33000
CY2019 us-gaap Interest Expense
InterestExpense
27000
CY2018 us-gaap Interest Expense
InterestExpense
21000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
686000
CY2019 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
332000
CY2018 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
53000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42026000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25223000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13809000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-121000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1074000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-42030000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-25102000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-12735000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.07
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.56
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.37
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.07
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.56
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.37
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20290966
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16064588
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9326810
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20290966
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16064588
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9326810
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-38000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
101000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42068000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25001000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12710000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
465000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
269000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
110000
CY2020 rcel Non Cash Lease Expense
NonCashLeaseExpense
502000
CY2019 rcel Non Cash Lease Expense
NonCashLeaseExpense
CY2018 rcel Non Cash Lease Expense
NonCashLeaseExpense
CY2020 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-259000
CY2019 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-397000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-95000
CY2020 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
43000
CY2019 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
6000
CY2018 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
15000
CY2020 rcel Provision For Inventory Obsolesence
ProvisionForInventoryObsolesence
84000
CY2019 rcel Provision For Inventory Obsolesence
ProvisionForInventoryObsolesence
89000
CY2018 rcel Provision For Inventory Obsolesence
ProvisionForInventoryObsolesence
31000
CY2020 rcel Issuance Of Common Stock To Directors In Lieu Of Directors Fees
IssuanceOfCommonStockToDirectorsInLieuOfDirectorsFees
107000
CY2019 rcel Issuance Of Common Stock To Directors In Lieu Of Directors Fees
IssuanceOfCommonStockToDirectorsInLieuOfDirectorsFees
CY2018 rcel Issuance Of Common Stock To Directors In Lieu Of Directors Fees
IssuanceOfCommonStockToDirectorsInLieuOfDirectorsFees
33000
CY2020 rcel Research And Development Tax Credit Benefits
ResearchAndDevelopmentTaxCreditBenefits
CY2019 rcel Research And Development Tax Credit Benefits
ResearchAndDevelopmentTaxCreditBenefits
-129000
CY2018 rcel Research And Development Tax Credit Benefits
ResearchAndDevelopmentTaxCreditBenefits
-1101000
CY2020 rcel Increase Decrease In Trade And Other Receivables
IncreaseDecreaseInTradeAndOtherReceivables
-729000
CY2019 rcel Increase Decrease In Trade And Other Receivables
IncreaseDecreaseInTradeAndOtherReceivables
-1291000
CY2018 rcel Increase Decrease In Trade And Other Receivables
IncreaseDecreaseInTradeAndOtherReceivables
-27000
CY2020 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-26000
CY2019 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1522000
CY2018 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1889000
CY2020 rcel Increase Decrease In Research And Development Tax Credits
IncreaseDecreaseInResearchAndDevelopmentTaxCredits
121000
CY2019 rcel Increase Decrease In Research And Development Tax Credits
IncreaseDecreaseInResearchAndDevelopmentTaxCredits
1742000
CY2018 rcel Increase Decrease In Research And Development Tax Credits
IncreaseDecreaseInResearchAndDevelopmentTaxCredits
26000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-219000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
315000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-174000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
468000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-17000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
94000
CY2020 rcel Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-476000
CY2019 rcel Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
CY2018 rcel Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2308000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
69000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
280000
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
693000
CY2019 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
737000
CY2020 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-366000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1435000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
42000
CY2019 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
62000
CY2018 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
61000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
474000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
252000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77057000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29709000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
590000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1021000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
365000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21295000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
156000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
53466000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9388000
CY2019 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
384000
CY2018 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
5000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
429000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-4000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-18000
CY2018 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-5000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22747000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19250000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12960000
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
257000
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
206000
CY2018 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-847000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1227000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-365000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
81702000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32453000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22791000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5077000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2934000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8072000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20374000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10986000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2914000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73840000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
42000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
27000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
21000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
85000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
15000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
3929000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22792000
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1435000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1423000
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
33000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
14032000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
32454000
CY2019 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2934000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1946000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
335000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
81702000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
5077000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16486000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
474000
CY2020 rcel Stock Issued During Period Value Vesting Of Rsu Options
StockIssuedDuringPeriodValueVestingOfRsuOptions
CY2020 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
107000
CY2020 rcel Cumulative Effect Period Of Adoption Adjusted Balance Value
CumulativeEffectPeriodOfAdoptionAdjustedBalanceValue
-55000
CY2020Q2 rcel Description Of Stock Exchange Ratio
DescriptionOfStockExchangeRatio
This exchange was conducted on the basis of one share of common stock of AVITA Therapeutics for every 100 ordinary shares of AVITA Medical, effecting an ‘implicit consolidation’ or ‘reverse split’. The holders of ordinary shares of AVITA Medical received one CDI for every 20 ordinary shares held in AVITA Medical, and the holders of AVITA Medical ADSs (each of which represented 20 ordinary shares in AVITA Medical) received one share of common stock in AVITA Therapeutics for every five ADSs held.
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including doubtful accounts, carrying value of long-lived asset, the useful lives of long-lived assets, accounting for income taxes and stock-based compensation) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, and trade and other receivables. As of June&#160;30, 2020, and 2019, substantially all of the Company&#8217;s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash is held. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2020, no single customer accounted for more than 10% of total </div><div style="font-size: 10pt; font-family: 'times new roman', serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; color: rgb(0, 0, 0);;display:inline;">revenues</div></div><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;or net accounts receivable. As of June&#160;30, 2019, one customer accounted for&#160;</div><div style="font-size: 10pt; font-family: 'times new roman', serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; color: rgb(0, 0, 0);;display:inline;">approximately </div></div><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10.5% of total revenues and&#160;</div><div style="font-size: 10pt; font-family: 'times new roman', serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; color: rgb(0, 0, 0);;display:inline;">three customers accounted for more than</div></div><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;10% of&#160;</div><div style="font-size: 10pt; font-family: 'times new roman', serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; color: rgb(0, 0, 0);;display:inline;">net accounts </div></div><div style="font-size: 10pt; font-family: 'times new roman', serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; color: rgb(0, 0, 0);;display:inline;">receivable, each representing approximately</div></div><div style="font-size: 10pt; font-family: 'times new roman', serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; color: rgb(0, 0, 0);;display:inline;"> 14.6%, 10.3% and 10.1</div></div><div style="font-size: 10pt; font-family: 'times new roman', serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; color: rgb(0, 0, 0);;display:inline;">% of total net accounts receivable. As of June 30, 2018, four customers accounted for more than 10% of total revenues, each representing approximately 17%, 14.5%, 12.8% and 10.4% of total revenues.</div></div><div style="font-size: 10pt; font-family: 'times new roman', serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; color: rgb(0, 0, 0);;display:inline;"></div></div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
66000
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
18000
CY2020Q2 rcel Cash In Foreign Institutions
CashInForeignInstitutions
466000
CY2019Q2 rcel Cash In Foreign Institutions
CashInForeignInstitutions
476000
CY2020 us-gaap Concentration Risk Customer
ConcentrationRiskCustomer
0
CY2019Q2 rcel Capitalized Patent Costs
CapitalizedPatentCosts
225000
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
18000
CY2018Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
17000
CY2017Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
68000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
43000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6000
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
15000
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
43000
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
5000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2800000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2900000
CY2018Q2 us-gaap Restricted Cash
RestrictedCash
0
CY2019Q2 us-gaap Concentration Risk Customer
ConcentrationRiskCustomer
1
CY2019Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
429000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
588000
CY2020Q2 rcel Operating Lease Liabilities Current
OperatingLeaseLiabilitiesCurrent
533000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2450000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M27D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
695000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
717000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
740000
CY2019Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
53000
CY2020Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
11000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
701000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
47000
CY2020 us-gaap Lease Cost
LeaseCost
748000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
675000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2020Q2 rcel Right Of Use Assets
RightOfUseAssets
2347000
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
26651
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
87000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2827000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
377000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
530000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
77000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
607000
CY2020Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
947000
CY2019Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
638000
CY2020Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
178000
CY2019Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
104000
CY2020 rcel Inventory Impairments
InventoryImpairments
306000
CY2019 rcel Inventory Impairments
InventoryImpairments
36000
CY2018 rcel Inventory Impairments
InventoryImpairments
0
CY2020Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2019Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
435000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P8M8D
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1136794
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
259633
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
99982
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
9270
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
339359
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.07
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0068
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0265
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.90
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.90
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
30.70
CY2020 dei Entity Registrant Name
EntityRegistrantName
Avita Therapeutics, Inc.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001762303
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1260524
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
501699
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M1D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
24679478
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
22185034
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
10520968
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.75
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.90
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.88
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0150
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0265
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.90
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.90
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0150
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
500000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.48
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
444543
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
39.12
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
605184
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
15.22
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
false
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020 dei Trading Symbol
TradingSymbol
RCEL
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-42030000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-25102000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-12735000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.07
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.56
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.37
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.56
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.37
CY2019Q3 us-gaap Revenues
Revenues
3250000
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
713000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
594000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
290000
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-20793000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-19899000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5382000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-21233000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5324000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-8427000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
4000
CY2019 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
-121000
CY2018 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
-1074000
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4162000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
4000
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-121000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-1074000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-121000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1074000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8827000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5297000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3805000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
4000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-1389000
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-299000
CY2018 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
120000
CY2019 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
121000
CY2018 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1074000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
-3794000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
535000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
391000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
669000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
84000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
796000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
2824000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13341000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4977000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-326000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.28
CY2019Q4 us-gaap Revenues
Revenues
3259000
CY2020Q1 us-gaap Revenues
Revenues
3877000
CY2020Q2 us-gaap Revenues
Revenues
3877000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
619000
CY2019Q4 us-gaap Cost Of Revenue
CostOfRevenue
846000
CY2020Q1 us-gaap Cost Of Revenue
CostOfRevenue
634000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
874000
CY2019Q3 us-gaap Gross Profit
GrossProfit
2631000
CY2019Q4 us-gaap Gross Profit
GrossProfit
2413000
CY2020Q1 us-gaap Gross Profit
GrossProfit
3243000
CY2020Q2 us-gaap Gross Profit
GrossProfit
3003000
CY2019Q3 us-gaap Other Operating Income
OtherOperatingIncome
2051000
CY2019Q4 us-gaap Other Operating Income
OtherOperatingIncome
386000
CY2020Q1 us-gaap Other Operating Income
OtherOperatingIncome
1008000
CY2020Q2 us-gaap Other Operating Income
OtherOperatingIncome
481000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2962000
CY2019Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3738000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3951000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3071000
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4558000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4145000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6361000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1635000
CY2018Q4 us-gaap Revenues
Revenues
1040000
CY2019Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19877676
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21215246
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2192000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2302000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15048000
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21372892
CY2018Q3 us-gaap Revenues
Revenues
269000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2332000
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
672000
CY2019Q4 us-gaap Share Based Compensation
ShareBasedCompensation
2903000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9048000
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3863000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
8340000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
13391000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
19657000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
16507000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3658000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-10592000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15406000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13023000
CY2019Q3 us-gaap Interest Expense
InterestExpense
11000
CY2019Q4 us-gaap Interest Expense
InterestExpense
9000
CY2020Q1 us-gaap Interest Expense
InterestExpense
5000
CY2020Q2 us-gaap Interest Expense
InterestExpense
8000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
103000
CY2019Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
99000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
363000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
121000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3566000
CY2019Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10502000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12910000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-3566000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-10502000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-15048000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-12914000
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18719857
CY2019Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19877676
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21215246
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21372892
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18719857
CY2019Q1 us-gaap Revenues
Revenues
1710000
CY2019Q2 us-gaap Revenues
Revenues
2455000
CY2018Q3 us-gaap Cost Of Revenue
CostOfRevenue
232000
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
505000
CY2019Q1 us-gaap Cost Of Revenue
CostOfRevenue
292000
CY2018Q4 us-gaap Cost Of Revenue
CostOfRevenue
242000
CY2018Q3 us-gaap Gross Profit
GrossProfit
37000
CY2018Q4 us-gaap Gross Profit
GrossProfit
798000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
37000
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2018Q3 us-gaap Interest Expense
InterestExpense
6000
CY2018Q4 us-gaap Interest Expense
InterestExpense
5000
CY2019Q1 us-gaap Interest Expense
InterestExpense
5000
CY2019Q2 us-gaap Interest Expense
InterestExpense
11000
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2019Q1 us-gaap Gross Profit
GrossProfit
1418000
CY2019Q2 us-gaap Gross Profit
GrossProfit
1950000
CY2018Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2163000
CY2018Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2840000
CY2019Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3309000
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3941000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2605000
CY2018Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3399000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3650000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3927000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1972000
CY2018Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2019000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1809000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2072000
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
217000
CY2018Q4 us-gaap Share Based Compensation
ShareBasedCompensation
593000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
567000
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
569000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
6957000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
8851000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
9335000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
10509000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5058000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6300000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6679000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7491000
CY2018Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
502000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-246000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5027000
CY2018Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6266000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6182000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7748000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-128000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-5034000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-6266000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-6182000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7620000
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13240087
CY2018Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14165200
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18263535
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18665604
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13240087
CY2018Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14165200
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18263535
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18665604
CY2018Q3 us-gaap Other Operating Income
OtherOperatingIncome
1862000
CY2018Q4 us-gaap Other Operating Income
OtherOperatingIncome
1753000
CY2019Q1 us-gaap Other Operating Income
OtherOperatingIncome
1238000
CY2019Q2 us-gaap Other Operating Income
OtherOperatingIncome
1068000
CY2020Q2 rcel Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
608000
CY2020Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
608000
CY2020Q2 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
17000
CY2019Q2 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
7000
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
564000
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
15000
CY2020Q2 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
255000
CY2019Q2 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
563000
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2996000
CY2020Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37756000
CY2019Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25358000
CY2020Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
285000
CY2019Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1000
CY2020Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42507000
CY2019Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25944000
CY2020Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41899000
CY2019Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25944000
CY2020Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
608000
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q2 rcel Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
-634000
CY2020 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10. Contingencies </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. As of June&#160;30, 2020, the Company does not have any outstanding or threatened litigation that would have a material impact to the financial statements. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
881000
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
667000
CY2020 us-gaap Depreciation
Depreciation
346000
CY2019 us-gaap Depreciation
Depreciation
269000
CY2018 us-gaap Depreciation
Depreciation
110000
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
792000
CY2019Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
933000
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
75000
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
125000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
100000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
70000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
16000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
15000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
15000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
125000
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
341000
CY2018Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
3.70
CY2020 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2019 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
119000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2018Q4 rcel Capital To Be Raised Through Private Placement
CapitalToBeRaisedThroughPrivatePlacement
28800000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2020Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
483000
CY2019Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
225000
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
119000
CY2020Q2 rcel Lease Deposits Current
LeaseDepositsCurrent
123000
CY2019Q2 rcel Lease Deposits Current
LeaseDepositsCurrent
40000
CY2020Q2 rcel Capitalized Patent Costs
CapitalizedPatentCosts
483000
CY2020Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
23000
CY2020Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21468494
CY2019Q4 dei Entity Public Float
EntityPublicFloat
963450796
CY2020Q2 rcel Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Determined Not To Be Probable
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptionsDeterminedNotToBeProbable
1900000
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4700000
CY2020 dei Entity Shell Company
EntityShellCompany
false

Files In Submission

Name View Source Status
0001193125-20-233145-index-headers.html Edgar Link pending
0001193125-20-233145-index.html Edgar Link pending
0001193125-20-233145.txt Edgar Link pending
0001193125-20-233145-xbrl.zip Edgar Link pending
d80602d10k.htm Edgar Link pending
d80602dex141.htm Edgar Link pending
d80602dex211.htm Edgar Link pending
d80602dex311.htm Edgar Link pending
d80602dex312.htm Edgar Link pending
d80602dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g80602g01g26.jpg Edgar Link pending
g80602g23n25.jpg Edgar Link pending
g80602g28w08.jpg Edgar Link pending
g80602g36z90.jpg Edgar Link pending
g80602g42d71.jpg Edgar Link pending
g80602g55a76.jpg Edgar Link pending
g80602g78e78.jpg Edgar Link pending
g80602g78k91.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rcel-20200630.xml Edgar Link completed
rcel-20200630.xsd Edgar Link pending
rcel-20200630_cal.xml Edgar Link unprocessable
rcel-20200630_def.xml Edgar Link unprocessable
rcel-20200630_lab.xml Edgar Link unprocessable
rcel-20200630_pre.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending